191 related articles for article (PubMed ID: 11037994)
21. Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1.
Yim JH; Siegel BA; DeBenedetti MK; Norton JA; Lairmore TC; Doherty GM
Surgery; 1998 Dec; 124(6):1037-42. PubMed ID: 9854580
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors.
Meko JB; Doherty GM; Siegel BA; Norton JA
Surgery; 1996 Dec; 120(6):975-83; discussion 983-4. PubMed ID: 8957483
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
24. Carcinoid tumors of the stomach: a clinical and radiographic study.
Binstock AJ; Johnson CD; Stephens DH; Lloyd RV; Fletcher JG
AJR Am J Roentgenol; 2001 Apr; 176(4):947-51. PubMed ID: 11264084
[TBL] [Abstract][Full Text] [Related]
25. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571
[TBL] [Abstract][Full Text] [Related]
26. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
27. Gastric carcinoids in patients with hypergastrinemia.
Jordan PH; Barroso A; Sweeney J
J Am Coll Surg; 2004 Oct; 199(4):552-5. PubMed ID: 15454137
[TBL] [Abstract][Full Text] [Related]
28. Recurrent ectopic adrenocorticotropic hormone producing thymic carcinoid detected with octreotide imaging.
Silva F; Vázquez-Sellés J; Aguilö F; Vázquez G; Flores C
Clin Nucl Med; 1999 Feb; 24(2):109-10. PubMed ID: 9988068
[TBL] [Abstract][Full Text] [Related]
29. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.
Schillaci O; Scopinaro F; Angeletti S; Tavolaro R; Danieli R; Annibale B; Gualdi G; Delle Fave G
J Nucl Med; 1996 Sep; 37(9):1452-6. PubMed ID: 8790191
[TBL] [Abstract][Full Text] [Related]
30. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
31. Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports.
Satta J; Ahonen A; Parkkila S; Leinonen L; Apaja-Sarkkinen M; Lepojärvi M; Juvonen T
Scand Cardiovasc J; 1999; 33(1):49-53. PubMed ID: 10093860
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
[TBL] [Abstract][Full Text] [Related]
33. Multiple endocrine neoplasia type 1: scintigraphic and magnetic resonance demonstration.
Nguyen BD; Wang EA
Clin Nucl Med; 1999 Jan; 24(1):73-4. PubMed ID: 9890506
[No Abstract] [Full Text] [Related]
34. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
35. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
36. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.
Norton JA; Melcher ML; Gibril F; Jensen RT
Surgery; 2004 Dec; 136(6):1267-74. PubMed ID: 15657586
[TBL] [Abstract][Full Text] [Related]
37. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
39. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67.
Belhocine T; Foidart J; Rigo P; Najjar F; Thiry A; Quatresooz P; Hustinx R
Nucl Med Commun; 2002 Aug; 23(8):727-34. PubMed ID: 12124477
[TBL] [Abstract][Full Text] [Related]
40. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids.
Debelenko LV; Emmert-Buck MR; Zhuang Z; Epshteyn E; Moskaluk CA; Jensen RT; Liotta LA; Lubensky IA
Gastroenterology; 1997 Sep; 113(3):773-81. PubMed ID: 9287968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
